Clinical Research Directory

Inclusion Criteria: 1. Subject age: ≤21 years 2. Body Surface Area (BSA): 1. Group A: BSA ≥0.5 m2 2. Group B: BSA \<0.5 m2 3. Planned for once-daily busulfan-containing conditioning regimen pre-bone marrow transplant 4. Scheduled to have TDM after the first dose of busulfan 5. Diagnosis: both benign and malignant conditions are eligible Exclusion Criteria: 1\. At the time of enrollment, patients may not receive medications that significantly alter busulfan clearance, as specified below. a. If patients had received the drugs listed below prior to enrollment, the following washout periods, based on ≥ 6 times drug t½, are required. Deferasirox: ≥7 days Metronidazole: ≥7 days Ketoconazole, voriconazole: ≥7 days Itraconazole, posaconazole: ≥14 days Phenytoin: ≥21 days